Anna Protopapas, Mersana Therapeutics CEO

J&J bets $40M cash on biotech's ADC tech and its bat­tle-test­ed CEO — with biobucks adding to $1B

Try­ing to see if it can find new us­es for a suite of an­ti­bod­ies its Janssen sub­sidiary has de­vel­oped, J&J has tapped Mer­sana Ther­a­peu­tics for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.